晚期HER-2阳性乳腺癌的最新治疗策略  

Latest Treatment Strategies of the Late HER-2 Positive Breast Cancer

作　　者：任瑞琴 刘剑锋 REN Rui-qin;LIU Jian-feng(Department of Clinical Pharmacy;Department of Oncology,Ningde Hospital of Traditional Chinese Medicine affiliated to Fujian University of Traditional Chinese Medicine,Ningde 352100,China)

机构地区：[1]福建中医药大学附属宁德中医院临床药学室,福建宁德352100 [2]福建中医药大学附属宁德中医院肿瘤科,福建宁德352100

出　　处：《海峡药学》2023年第11期79-82,共4页Strait Pharmaceutical Journal

摘　　要：曲妥珠单抗治疗早期人表皮生长因子受体-2(Human epidermal growth factor receptoe-2,HER-2)阳性乳腺癌临床疗效确切,同时也是晚期HER-2阳性乳腺癌解救的一线治疗方案,但其耐药率限制了临床的应用。本文通过对晚期HER-2阳性乳腺癌治疗策略进行回顾与总结,从目前抗HER-2靶向治疗药物、晚期HER-2阳性乳腺癌的最新治疗策略、晚期HER-2阳性乳腺癌与靶向联合时化疗药物的选择、晚期HER-2阳性乳腺癌转移灶的处理几个方面进行综述,提出《中国临床肿瘤学会(CSCO)乳腺癌诊疗指南(2023版)》已推荐注射用德曲妥珠单抗(T-Dxd)作为二线治疗方案,以期为进一步的研究及制定临床治疗方案提供参考。Trastuzumab has a definite clinical efficacy in the treatment of early human epidermal growth factor receptor-2(HER-2)positive breast cancer,and it is also a first-line treatment plan for the rescue of advanced breast cancer with HER-2 positive,but its drug resistance rate limits its clinical application.This article reviews and summarizes the treatment strategies for advanced HER-2 positive breast cancer,including the latest treatment strategy for advanced HER-2 positive breast cancer,anti HER-2 targeted treatment drugs,the choice of chemotherapy drugs for advanced HER-2 positive breast cancer when combined with targeting,and the treatment of metastasis of advanced HER-2 positive breast cancer.The Chinese Society of Clinical Oncology(CSCO)Guidelines for Diagnosis and Treatment of breast cancer(2023 Edition)has recommended T-Dxd as a second-line treatment plan,with a view to providing reference for further research and development of clinical treatment plans.

关 键 词：HER-2阳性 乳腺癌 最新治疗策略 T-Dxd 

分 类 号：R969.4[医药卫生—药理学]